Monthly Archives: December 2015

Be thankful to smallest favors Air Commodore Vishal was a Jet Pilot. In a combat mission his fighter plane was destroyed by a missile. He however ejected himself and parachuted safely. He won acclaims and appreciations from many. After five years one day he was sitting with his wife in a restaurant. A man from another table came to him ... Read More »

SMS Pharma rises 12% on USFDA nod for Andhra Pradesh plant Shares of SMS Pharmaceuticals climbed 11.8 percent in early trade Monday on getting approval from the US health regulator for one of its unit in Andhra Pradesh. “SMS has received approval from the US Food and Drug Administration (USFDA) for manufacturing facility (unit 7) located at Kandivalasa village, Pusapatirega ... Read More »

Indian pharma market crosses Rs 1,00,000 crore mark: IMS Health MUMBAI: The Indian pharmaceutical market has for the first time crossed the Rs 100000 crore mark in November when calculated on the basis of Moving Annual Total (MAT), said IMS Health, a global pharmaceutical market research firm. In its monthly review of the local market, IMS Health said in its ... Read More »

FDA approves Wellstat’s Vistogard for chemotherapy overdose The US Food and Drug Administration (FDA) has approved Wellstat Therapeutics’ Vistogard (uridine triacetate) to treat overdose of fluorouracil or capecitabine, which are administered for several malignancies. Vistogard is claimed to be the first antidote for emergency treatment of 5-fluorouracil (5-FU) overdose treatment available to patients. It is also indicated for patients exhibiting ... Read More »

The Stone Cutter Once upon a time there lived a stone cutter ,in a small village. All day long he worked hard, cutting the hard stones and making the shape which were needed by his customers. His hands were hard and his clothes were dirty. One day he ... Read More »

Can Pfizer finally orchestrate a winning megamerger after so many disappointments? Pfizer’s ($PFE) decision to buy Allergan ($AGN) wasn’t much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEO Ian Read‘s desired tax inversion. Nor is it surprising that Pfizer chose to rack up another megamerger, given its history of huge deals. ... Read More »

Heptares Therapeutics, Pfizer partner for GPCR-focused drug discovery Heptares Therapeutics and Pfizer have signed a drug discovery collaboration agreement, focused on G protein-coupled receptor (GPCR) targets across several therapeutic areas. Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer stabilized GPCRs ... Read More »